Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib (Sutent, SU11248) in Patients With Cancer.

Trial Profile

Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib (Sutent, SU11248) in Patients With Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2012

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Cancer
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms CLEARSUN
  • Most Recent Events

    • 11 Jul 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top